Clinical trial · Interventional
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
NCT01627288CI-TRIAL-00049909IDEALcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Cervix | Malignant Cervical Neoplasm | ALIAS | 0.90 |
| Cervical Neoplasms | Cervical Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Boost radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Boost Radiation: Dose Level 1
- description
- 2.4 Gy X 25 fractions = 60 Gy
- interventionNames
- Radiation: Boost radiation
- type
- EXPERIMENTAL
- label
- Boost Radiation: Dose level 2
- description
- 2.6 Gy X 25 fractions = 65 Gy
- interventionNames
- Radiation: Boost radiation
- type
- EXPERIMENTAL
- label
- Boost Radiation: Dose level 3
- description
- 2.8 Gy x 25 fractions = 70 Gy
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy confirmed malignancy of the gynecologic tract * Involved pelvic or para-aortic lymph nodes * Treatment plan to include delivery of concurrent chemoradiotherapy. * Good performance status * Negative pregnancy test in women of child-bearing potential * Signed study-specific informed consent * Lab results within study specific limits Exclusion Criteria: * Prior radiation to the abdomen or pelvis * A history of Scleroderma or Inflammatory bowel disease * Contraindication to chemotherapy or radiation
References
Publications (0)
Data not yet available
No reference posted for this study.